The Patent Estate Problem: Why Litigation Finance Is the Only Preservation Tool American Inventors Actually Have

Congress and the courts have spent two decades treating patents as active weapons in an ongoing commercial fight. That framing misses what patents actually are to most of the people who own them: inheritable property. Twenty-year terms outlast careers. Portfolios pass to spouses, children, foundations, and trusts. Licensing income can support a family for a generation after the inventor stops working.

That is the design. The reality, for independent inventors and small technology companies, is different. The current enforcement architecture systematically strips value from patents while their owners are alive and virtually guarantees that whatever value remains at death cannot be preserved through the mechanisms every other class of asset uses. Litigation finance is often described as an access-to-justice tool. The more urgent framing is that it is one of the only tools American inventors have to protect the estate value of what they built.

The pending fights over funder disclosure — Suggestion 26-CV-8 before the Advisory Committee on Civil Rules, the USITC’s proposed 19 C.F.R. § 210.14a, and S.3826, the Litigation Funding Transparency Act of 2026 — are not really arguments about transparency. They are arguments about whether a solo inventor’s family keeps what the inventor spent 30 years building.

Estate Value is Measurable, and It Is Being Taken

The most rigorous empirical work on inter partes review (IPR) economics — Sidak and Skog’s Attack of the Shorting Bass in the UCLA Law Review — used event-study methods to measure the abnormal stock-price effect of Kyle Bass’s Hayman Capital IPR petitions. Their first challenge, against Acorda Therapeutics on February 10, 2015, produced a one-day abnormal return of –11.94% (t = –3.67) and a three-day abnormal return of –10.78%. That is not a general market reaction. That is investors accurately pricing what a single IPR petition does to a patent portfolio.

For a public company, that is a bad quarter. For a private inventor whose net worth is his patent portfolio, the same percentage drop is his retirement. Unlike the public company, he has no visible market price to prove the loss existed. When his estate is later valued for tax purposes, for a buy-sell transaction, or for a family transfer, the depressed number is the only number that exists. The valuation loss is silent and permanent.

Repeat that across the Patent Trial and Appeal Board’s (PTAB’s) fiscal-year kill rate — 61% to 70% of cases reaching final written decisions still find all claims unpatentable — and the scale of the transfer becomes visible. Every serial reexamination, every institution decision that goes the wrong way, every appeal delay, is a valuation event on an asset most inventors need to leave intact for their families. The AIPLA median cost figures — roughly $1 million through trial for cases with $1 million–$10 million at risk, up to $3.6 million through appeal above $25 million — are how the estate is dismantled from the outside.

What Every Other Asset Class Already Has

An inventor with $50 million in real estate has partition rules, 1031 exchanges, tenancy in common (TIC) structures, mortgage financing, cost-segregation depreciation, and a mature secondary market. An inventor with $50 million in operating-company equity has Employee Stock Ownership Plans, Grantor Retained Annuity Trusts, Intentionally Defective Grantor Trust sales, buy-sell insurance, and family limited partnerships. An inventor with $50 million in art has fractional-ownership vehicles, private-placement lending, catalogue insurance, and named auction houses.

An inventor with $50 million in patents has none of those. The United States has the doctrinal plumbing: In re Cybernetic Services, 252 F.3d 1039 (9th Cir. 2001) settled that a security interest in a patent is perfected by state UCC-1 filing, not by U.S. Patent and Trademark Office (USPTO) recordation. But no lender takes patents as collateral at scale because any accused infringer can file an IPR at any point in the 20-year term. On institution, the challenge imposes a 61%–70% probability of losing the claims that secure the loan. Perfection is not the problem. Post-loan validity risk is. There is no standardized IP-holding vehicle recognized for estate-tax valuation discounts, no accepted title-insurance product for licensing rights, and no secondary market where heirs can price a portfolio against a public benchmark.

The rest of the developed world is moving. The World Intellectual Property Organization (WIPO) launched its Action Plan for IP Finance in November 2022, aiming to move intangible-asset finance “from the margins to the mainstream.” The European Union Intellectual Property Office (EUIPO) published a comprehensive IP-backed finance analysis in 2026. Korea, Singapore, and the UK run functioning IP-collateralized lending programs. In 2020, Bermuda’s government-empaneled Intellectual Property Taskforce — on which I served as one of five official members — proposed IP-backed financing, dedicated IP insurance products, and a specialized IP court.

None of that infrastructure exists at scale in the United States. What does exist is litigation finance. That is not a coincidence. Each of those foreign frameworks assumes what American courts have quietly withdrawn: that a valid patent, unchallenged, is a bankable asset. Without that assumption, no lender extends against IP, no insurer underwrites title, and litigation finance is left as the only preservation tool the market has produced. It filled the gap because nothing else could.

The Disclosure Fight as a Taking-in-Installments

Every current federal disclosure proposal — the March 10, 2026 LCJ/ILR rules suggestion (covered in IPWatchdog’s March 12, 2026 report), the USITC’s April 30, 2026 NPRM proposing 19 C.F.R. § 210.14a, and S.3826 — is framed as transparency reform. Read against the estate-value problem, they are something else.

Each imposes disclosure on plaintiffs. None imposes comparable added disclosure on defendants — which matters because the federal rules already regulate defendant-side financial disclosure in a way the pending proposals refuse to mirror. FRCP 26(a)(1)(A)(iv) has since 1970 required defendants to produce, without request, “any insurance agreement under which an insurance business may be liable to satisfy all or part of a possible judgment.” That disclosure is paired with FRE 411, which forbids using insurance evidence “to prove whether the person acted negligently or otherwise wrongfully.” The rules operate as a unit: disclosure enables realistic case valuation; the evidentiary bar prevents disclosure from being weaponized at trial.

The pending funder proposals invert both halves of that framework. They compel the plaintiff to reveal capital structure, exit economics, reversion clauses, settlement-consent thresholds, and termination triggers, with no counterpart to FRE 411 restraining use in negotiation, cross-examination, or motions practice. And they extend nothing new to the defendant side. Patent-defense reserves, cost-sharing among co-defendants, joint-defense-group budgets, indemnity backstops from customers and upstream suppliers, and — crucially — the same litigation-finance arrangements when a defendant uses them are exempt or protected as work product. The plaintiff’s capital structure is exposed. The defendant’s mirror-image structure is not.

That asymmetry is not a drafting oversight. It is the mechanism. Once a defendant knows the funder’s return curve, it no longer negotiates against the patent — it negotiates against the funder’s economics. Force enough disclosure and the funder charges more; force more and the funder walks. When the funder walks, the inventor negotiates on defendant terms, drops the case, or sells the patent below intrinsic value. Each outcome takes value from the inventor’s estate and transfers it to the accused infringer.

This is not a first-principles argument against disclosure. It is an argument for treating funder disclosure the way the federal rules already treat insurance disclosure: symmetrically, and with a use restriction. An honest reform would (i) require the defendant to disclose comparable indemnity, cost-sharing, defense-funding, and any insurance beyond what Rule 26(a)(1)(A)(iv) already requires, and (ii) adopt an FRE 411-style bar preventing either side’s disclosed financing from being used to prove the merits. None of the pending proposals does either.

Four Questions Worth Debating

• Should funder disclosure be structured the way Rule 26(a)(1)(A)(iv) and FRE 411 already handle insurance — mandatory, symmetric, paired with a use restriction? If yes, every pending proposal needs redrafting. If no, disclosure advocates should explain what makes plaintiff financing categorically different from defendant insurance.
• Should Congress cure the IP-collateral defect directly? Cybernetic Services settled perfection. The unresolved defect is post-loan validity risk. A narrow federal fix would (i) create a bona-fide-lender safe harbor immunizing a perfected patent security interest from cancellation during the loan term, and (ii) shift the resulting valuation loss to a challenger who files an IPR against a collateralized patent and loses.
• Should IRS estate-tax valuation of patents be conformed to the underlying doctrinal reality? Rul. 59-60 defines fair market value as the price between a willing buyer and seller “having reasonable knowledge of relevant facts.” A knowledgeable buyer would discount for the 61%–70% PTAB kill rate and for pending or threatened IPRs. Estates are nevertheless routinely assessed at undiscounted face value. Guidance should recognize PTAB exposure as a Section 2031 valuation adjustment and permit Section 2032 alternate valuation to reflect a later institution decision. Otherwise, an estate can be assessed at 40% on value the government’s own tribunal is simultaneously destroying.
• Should the PTAB institution decision itself be treated as a taking? — measurable, quantifiable, compensable — when the resulting cancellation is later overturned on appeal? The Sidak/Skog data suggest the valuation loss is real, immediate, and, in total, systemic.
• Should the AIPLA Economic Survey cost figures and the published PTAB kill-rate ranges be treated as standard inputs in estate-plan valuation memoranda whenever a decedent held enforceable patents? Practitioners recommending inventor families cannot responsibly value a portfolio at undiscounted face when the numbers to discount it are public.

The Bridge Until Reform

None of the pending federal fixes — the PREVAIL Act (S.1553), the RESTORE Patent Rights Act (S.708/H.R.1574), or Director Squires’ March 11, 2026 memorandum adding U.S.-manufacturing considerations to PTAB discretionary institution — will restore the estate value the last 20 years have already stripped from inventor portfolios. What they may do, if enacted seriously, is stop the further transfer. Until then, litigation finance is the only tool bridging the gap between owning a patent and being able to defend it long enough to preserve its value for the next generation. Constraining that tool without replacing it is not transparency policy. It is estate policy — and it is being made without the estate side of the argument in the room.

American inventors built infrastructure the country still runs on. They should not have to watch its estate value vanish through procedural attrition while every other asset class enjoys mature preservation tools. If the pending disclosure regime moves forward without symmetric application and without a serious domestic IP-finance framework to backstop it, the practical result will be a generational transfer of wealth out of inventor families and into the balance sheets of the companies that outlasted them. That is not a transparency outcome. It is a taking, executed in installments, through Rule 26.

Image Source: Deposit Photos
Author: kchungtw
Image ID: 130677098